A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
Pfizer
Cancer Research UK
Pfizer
Amgen
Tianjin Medical University
Hoffmann-La Roche
National Cancer Institute (NCI)
Cancer Research UK
Ikena Oncology
Eli Lilly and Company
Aminex Therapeutics, Inc.
Novartis
Five Prime Therapeutics, Inc.
Weill Medical College of Cornell University
University College, London
AHS Cancer Control Alberta
GE Healthcare
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center